Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/309 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME10883158
PMID: | 10883158
LR: | 20061115
CED: | 20000726
DCO: | 20000726
Autoren: | Debi R; Robinson D; Agar G; Halperin N
Titel: | GAG for osteoarthritis of the knee--a prospective study
Quelle: | Harefuah; VOL: 138 (6); p. 451-3, 518 /20000315/
PM: | Print
SU: | IM
Sprache: | Hebrew
CY: | ISRAEL
JID: | 0034351
ISSN: | 0017-7768
CO: | HAREA6
Institution: | Orthopedic Dept., Assaf Harofeh Medical Center, Zrifin.
DT: | Clinical Trial; Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial
Schlagwörter
CT: | ADULT; AGED; AGED, 80 AND OVER; CHONDROITIN SULFATES/*therapeutic use; FEMALE; GLUCOSAMINE/*therapeutic use; GLYCOSAMINOGLYCANS/therapeutic use; HUMANS; KNEE JOINT/*; MALE; MIDDLE AGED; OSTEOARTHRITIS/*drug therapy; OSTEOARTHRITIS/physiopathology; PLACEBOS; PROSPECTIVE STUDIES; RANGE OF MOTION, ARTICULAR
CTG: | ERWACHSENER; ALTE MENSCHEN; ALTE MENSCHEN, 80 JAHRE UND ÄLTER; CHONDROITINSULFATE/*therapeutische Anwendung; WEIBLICH; GLUCOSAMIN/*therapeutische Anwendung; GLYCOSAMINO-GLYCANE/therapeutische Anwendung; MENSCH; KNIEGELENK/*; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; OSTEOARTHROSE/*Arzneimitteltherapie; OSTEOARTHROSE/Pathophysiologie; PLAZEBOS; PROSPEKTIVE STUDIEN; BEREICH DER GELENKBEWEGLICHKEIT
TE: | Glycosaminoglycans; Placebos; Glucosamine/3416-24-8; Chondroitin Sulfates/9007-28-7
CR: | 3416-24-8; 9007-28-7
AB: | Osteoarthritis results from progressive catabolic loss of cartilage proteoglycans due to imbalance between synthesis and degradation. The availability of glucosamine, an intermediate in mucopolysaccharide synthesis, can be rate-limiting for proteoglycan production in cartilage tissue culture. 57 patients suffering from osteoarthritis of the knee were randomized into a group treated for 4 weeks with daily i.v. glucosamine sulfate (GS) together with 800 mg chondroitin sulfate, and a placebo group. Knee pain at rest, on movement and on palpation, as well as range of knee motion were then recorded. In the GS group, there was significant reduction of clinical symptoms (p < 0.01), but no significant reduction in the placebo group. Physicians' assessment of tenderness and range of motion were significantly in favor of the GS group (p < 0.01). In those treated with glycosamine there were no adverse reactions and no changes in laboratory blood tests. We conclude that GS can be considered the drug of choice for prolonged treatment of osteoarthritis.

» Volltext »
» Fenster schließen »